Form 4: Kymera Therapeutics Director Bruce Booth Granted 16,000 Stock Options

Kymera Therapeutics, Inc. Director Bruce Booth was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Summary

• Bruce Booth, a Director of Kymera Therapeutics, Inc. (KYMR), was granted 16,000 stock options.
• The stock options have an exercise price of $46.47 per share.
• The grant date for these options was June 25, 2025.
• The options are set to vest in full upon the earlier of June 25, 2026, or the date of the next annual meeting of the Issuer's stockholders.
• The expiration date for these stock options is June 24, 2035.
• It is disclosed that the proceeds from any sale of shares issued upon the exercise of these options will be transferred to Atlas Venture Life Science Advisors, LLC, with Mr. Booth disclaiming ownership except for any pecuniary interest.

Sentiment

Score: 5

Explanation: The document reports a routine stock option grant to a director, which is a standard compensation practice and does not inherently indicate positive or negative sentiment regarding the company's operational performance or outlook.

Positives

• The grant of 16,000 stock options to a director aligns their interests with shareholder value, as the options become more valuable if the stock price increases above the exercise price of $46.47.

Negatives

• The reporting person, Bruce Booth, disclaims direct ownership of the securities, as proceeds from any sale upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, which may reduce the direct personal incentive alignment for the individual director.

Risks

• The value of the stock options is subject to market fluctuations; if Kymera Therapeutics' common stock price does not exceed the exercise price of $46.47, the options may not be profitable or may expire worthless.

Future Outlook

The granted stock options are set to vest in full by June 25, 2026, or earlier upon the date of the next annual meeting of the Issuer's stockholders, indicating a future milestone for this compensation.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a stock option grant to a director, which is a common practice in the biotechnology and pharmaceutical industry for executive and board compensation to align interests with long-term company performance.

Corporate Governance

Related Party Transactions

• Proceeds from the sale of shares upon exercise of the stock options granted to Director Bruce Booth will be transferred to Atlas Venture Life Science Advisors, LLC, indicating a related party arrangement concerning the director's compensation structure.

Stakeholder Impact

• Shareholders: The grant of stock options is a form of equity-based compensation that aligns the director's interests with shareholder value, contingent on the stock price exceeding the exercise price. However, the disclosure that proceeds will go to Atlas Venture Life Science Advisors, LLC, rather than directly to the director, may be noted by shareholders regarding the director's direct personal financial incentive.

Next Steps

• Vesting of 16,000 stock options by June 25, 2026, or the date of the next annual meeting of stockholders.
• Potential exercise of stock options by the reporting person before the expiration date of June 24, 2035.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Beneficial Ownership, Equity Compensation